Confirmatory Study of MH002 for Active Ulcerative Colitis
This study is testing MH002, a microbiome-based live biotherapeutic product (a medicine with live bacteria) for people with active ulcerative colitis (UC). UC is a bowel disease causing inflammation and sores. MH002 aims to restore normal gut function. Researchers want to see if MH002 is safe and effective. Two different doses of MH002, given as a capsule once daily, will be compared to a placebo (an inactive capsule). You may be able to join if you are at least 16 years old and have been diagnosed with active mild-to-moderate UC for at least three months. The main goal is to see how much your colon's inflammation improves after 12 weeks.
- Study design
- This interventional study plans to enroll 204 participants. It will test two different doses of MH002 against a placebo.
- What's involved
- Participants will take an oral capsule once daily. The primary endpoint is measured at Week 12, suggesting at least 12 weeks of participation.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at Week 12. Long-term treatment effects will be investigated, but specific follow-up duration is not detailed.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07296315
Confirmatory Clinical Study in Active Ulcerative Colitis
Recruiting
PHASE2Ages 16+InterventionalTreatmentMRM Health NV
~204 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:Low-dose MH002High-dose MH002Placebo
At a glance
Recruiting sites
16 of 16 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in centrally-assessed Mayo Endoscopic Subscore (MES) at Week 12.
Measured over Week 12
Conditions
Where it's being run
16 sites across 5 statesGeorgia9
Florida3
North Carolina2
Texas1
Moldova1
Study leadership
- Ludo Haazen, MD · STUDY_CHAIR · MRM Health NV
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Documented diagnosis (histologic diagnosis and either endoscopic or radiographic diagnosis) of ulcerative colitis (UC) at least 3 months prior to Screening.
Diagnosis of active mild-to-moderate UC at Screening as defined by an mMS of 4 to 7, including a MES ≥2 (confirmed by central reading), a Mayo Rectal Bleeding score of 1 or 2, and a Mayo Stool Frequency score ≥1.
UC lesions extending ≥10 cm from the anal verge.
Participant must either receive a stable dose of orally administered 5-aminosalicylic acid (5-ASA); have failed, due to insufficient efficacy, oral 5-ASA; have a documented intolerance or poor tolerance to an aminosalicylic acid treatment, including 5-ASA, or be contra-indicated to receive 5-ASA treatment per local labeling.
Participant must provide written informed consent or assent (parent or legal guardian must provide consent for a participant \<18 years of age who has assented to participate in the study, or as required per local regulations).
In countries not allowing females of childbearing potential (FOCBP) to participate without an acceptable contraceptive method, the FOCBP must agree to abide to local requirements and eg, use at least an acceptable method of contraception until the end of treatment.
Exclusion
Diagnosis of Crohn's disease, undetermined colitis, ischemic colitis, fulminant colitis, or toxic megacolon.
Evidence of a clinically significant, active infection of the gastrointestinal tract.
Severe UC (mMS\>7), meeting modified Truelove Witts' criteria and/or RB score of 3, participant with ulcerative proctitis only, or participant in whom colitis is most severe in the transverse colon or ascending colon, or if any hospitalization is planned at the time of Screening.
Total colectomy, stoma, or ileo-anal pouch, or history of extensive colonic resection leaving less than 30 cm of colon.
Presence of intra-abdominal fistula, abscesses, diverticulitis, or gastrointestinal bleeding unrelated to UC.
History of colon carcinoma or high-grade dysplasia.
Previous use of any advanced UC treatment, including any anti-TNF (eg, infliximab), antiintegrin (eg, vedolizumab) or anti-IL-12/23 (eg, ustekinumab) agent, anti-IL23 (eg, risankizumab), Janus kinase inhibitors (eg, tofacitinib), and sphingosine-1-phosphate receptor modulators (eg, etrasimod).
Use of sulfasalazine ≤4 weeks prior to randomization.
Use of corticosteroids or any disease-modifying antirheumatic drugs (DMARD), including thiopurines, ≤6 weeks prior to randomization into the study, except for a stable, low dose of oral corticosteroids (≤10 mg prednisolone/day) for at least 2 weeks prior to Screening colonoscopy and up to at least the Week 12 visit.
Use of antibiotics (except for local use), prebiotics, or probiotics ≤4 weeks prior to randomization or anticipated during study participation, or concomitant, chronic use of an antidiarrheal drug, or concomitant use of any rectal treatment.
Use of fecal microbiota transplantation (FMT) ≤52 weeks prior to randomization.
Treatment with another investigational drug or intervention within 30 days prior to Screening, or within 5 times the elimination half-life of the investigational drug (whichever is longest).
Any immunocompromised state, including conditions linked to severe immunosuppression (eg, active human immunodeficiency virus, malignancies, liver cirrhosis, systemic chemotherapy).
Leukopenia (total white blood cell count \<3000/μL) and/or neutropenia (absolute neutrophil count \<1000/μL), anemia (hemoglobin \<10.0 g/dL), thrombocytopenia (peripheral blood platelet count \<100 × 10\^9/L), and/or any coagulation disorder with significantly increased risk of bleeding.
Ongoing or recent (\<3 months) renal disease or insufficiency as manifested, eg, by medical history and/or clinical examination and/or (calculated or measured) glomerular filtration rate ≤60 mL/min.
Ongoing or recent (\<3 months) advanced hepatic dysfunction defined as a Child Pugh score ≥10 (Class C), or increase ≥2 times the upper limit of normal in aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TB), prothrombin time (PT) or international normalised ratio (INR).
Clinically significant bone marrow disease if progressive or not controlled, or any history of solid organ or bone marrow transplantation.
Active intravenous drug abuse or alcohol abuse disorder as assessed by the Investigator.
Pregnancy or lactation at study entry. Note: Participants who become pregnant or start to breastfeed during the study may continue the study per the Investigator's discretion.
Participants who are inappropriate for the study per the Investigator's discretion.
An employee (or a relative of) of the Investigator, study center, contract research organization, or Sponsor.
What this trial measures
- Change from baseline in centrally-assessed Mayo Endoscopic Subscore (MES) at Week 12.Week 12
The MES ranges from 0 to 3, with higher scores indicating more severe disease.